Formalin-treated UV-inactivated SARS coronavirus vaccine retains its immunogenicity and promotes Th2-type immune responses

Japanese Journal of Infectious Diseases

Volumn 60, Issue 2-3, 2007, Pages 106-112

  Tsunetsugu Yokota, Yasuko ^a   Ato, Manabu ^a   Takahashi, Yoshimasa ^a   Hashimoto, Shu Ichi ^a   Kaji, Tomohiro ^b   Kuraoka, Masayuki ^a   Yamamoto, Ki Ichi ^a   Mitsuki, Yu Ya ^a   Yamamoto, Takuya ^a   Oshima, Masamichi ^a   Ohnishi, Kazuo ^a   Takemori, Toshitada ^b  

^a NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^b RIKEN YOKOHAMA INSTITUTE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FORMALDEHYDE; IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 4; NEUTRALIZING ANTIBODY; SEVERE ACUTE RESPIRATORY SYNDROME VACCINE; VIRUS ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DETECTION; ARTICLE; BONE MARROW; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE SEVERITY; DRUG EFFICACY; DRUG FORMULATION; DRUG INACTIVATION; DRUG SAFETY; FEMALE; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; MOUSE; NONHUMAN; SEVERE ACUTE RESPIRATORY SYNDROME; TH2 CELL; ULTRAVIOLET RADIATION; VIRION;

ANIMALS; ANTIBODIES, VIRAL; FEMALE; FORMALDEHYDE; HUMANS; MICE; MICE, INBRED BALB C; SARS VIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; TH2 CELLS; ULTRAVIOLET RAYS; VACCINES, INACTIVATED; VIRAL VACCINES;

EID: 34347326026     PISSN: 13446304     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Drosten, C., Gunther, S., Preiser, W., et al. (2003): Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N. Engl. J. Med., 348, 1967-1976.
2. Ksiazek, T.G., Erdman, D., Goldsmith, C.S., et al. (2003): A novel coronavirus associated with severe acute respiratory syndrome. N. Engl. J. Med., 348, 1953-1966.
3. Holmes, K.V. and Enjuanes, L. (2003): Virology. The SARS coronavirus: a postgenomic era. Science, 300, 1377-1378.
4. Matra, MA., Jones, S.J., Astell, C.R., et al. (2003): The genome sequence of the SARS-associated coronavirus. Science, 300, 1399-1404.
5. Li, W., Moore, M.J., Vasilieva, N., et al. (2003): Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature, 426, 450-454.
6. Wong, S.K., Li, W., Moore, M.J., et al. (2003): A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2. J. Biol. Chem., 279, 3197-3201.
7. Li, G., Chen, X. and Xu, A. (2003): Profile of specific antibodies to the SARS-associated coronavirus. N. Engl. J. Med., 349, 508-509.
8. Clarke, T. (2003): SARS what have we learned? What about vaccine? Nature, 424, 126.
9. Yang, Z.Y., Kong, W.P., Huang, Y., et al. (2004): A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. Nature, 428, 561-564.
10. Tsunetsugu-Yokota, Y., Ohnishi, K. and Takemori, T. (2006): Severe acute respiratory syndrome (SARS) coronavirus: application of monoclonal antibodies and development of an effective vaccine. Rev. Med, Virol., 16, 117-131.
11. Buchholz, U.J., Bukreyev, A., Yang, L., et al. (2004): Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity. Proc. Natl. Acad. Sci. USA, 101, 9804-9809.
12. Bukreyev, A., Lamirande, E.W., Buchholz, U.J., et al. (2004): Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS. Lancet, 363, 2122-2127.
13. Ishii, K., Hasegawa, H., Nagata, N., et al. (2006): Induction of protective immunity against severe acute respiratory syndrome coronavirus (SARS-CoV) infection using highly attenuated recombinant vaccinia virus DIs. Virology, 351, 368-380.
14. Takasuka, N., Fujii, H., Takahashi, Y., et al. (2004): A subcutaneously injected UV-inactivated SARS coronavirus vaccine elicits systemic humoral immunity in mice. Int. Immunol., 16, 1423-1430.
15. Ohnishi, K., Sakaguchi, M., Kaji, T., et al. (2005): Immunological detection of severe acute respiratory syndrome coronavirus by monoclonal antibodies. Jpn. J. Infect. Dis., 58, 88-94.
16. Liu, X., Shi, Y., Li, P., et al. (2004): Profile of antibodies to the nucleocapsid protein of the severe acute respiratory syndrome (SARS)-associated coronavirus in probable SARS patients. Clin. Diagn. Lab. Immunol., 11, 227-228.
17. Shi, Y., Yi, Y., Li, P., et al. (2003): Diagnosis of severe acute respiratory syndrome (SARS) by detection of SARS coronavirus nucleocapsid antibodies in an antigen-capturing enzyme-linked immunosorbent assay. J. Clin. Microbiol., 41, 5781-5782.
18. Faber, M., Lamirande, E.W., Roberts, A., et al. (2005): A single immunization with a rhabdovirus-based vector expressing severe acute respiratory syndrome coronavirus (SARS-CoV) S protein results in the production of high levels of SARS-CoV-neutralizing antibodies. J. Gen. Virol., 86, 1435-1440.
19. Gao, W., Tamin, A., Soloff, A., et al. (2003): Effects of a SARS-associated coronavirus vaccine in monkeys. Lancet, 362, 1895-1896.
20. Holmes, K.V. (2005): Structural biology. Adaptation of SARS coronavirus to humans. Science, 309, 1822-1823.
21. Slifka, M.K., Matloubian, M. and Ahmed, R. (1995): Bone marrow is a major site of long-term antibody production after acute viral infection. J. Virol., 69, 1895-1902.
22. Moran, T.M., Park, H., Fernandez-Sesma, A., et al. (1999): Th2 responses to inactivated influenza virus can Be converted to Th1 responses and facilitate recovery from heterosubtypic virus infection. J. Infect. Dis., 180, 579-585.
23. Qu, D., Zheng, B., Yao, X., et al. (2005): Intranasal immunization with inactivated SARS-CoV (SARS-associated coronavirus) induced local and serum antibodies in mice. Vaccine, 23, 924-931.
24. Xiong, S., Wang, Y.F., Zhang, M.Y., et al. (2004): Immunogenicity of SARS inactivated vaccine in BALB/c mice. Immunol. Lett., 95, 139-143.
25. Zhang, C.H., Lu, J.H., Wang, Y.F., et al. (2005): Immune responses in Balb/c mice induced by a candidate SARS-CoV inactivated vaccine prepared from F69 strain. Vaccine, 23, 3196-3201.
26. Jackwood, M.W. and Hilt, D.A. (1995): Production and immunogenicity of multiple antigenic peptide CMAP) constructs derived from the S1 glycoprotein of infectious bronchitis virus (IBV). Adv. Exp. Med. Biol., 380, 213-219.
27. Liu, J., Lim, S.L., Ruan, Y., et al. (2005): SARS transmission pattern in Singapore reassessed by viral sequence variation analysis. PLoS Med., 2, e43.
28. See, R.H., Zakhartchouk, A.N., Petric, M., et al. (2006): Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus. J. Gen. Virol., 87, 641-650.
29. Stevens, T.L., Bossie, A., Sanders, V.M., et al. (1988): Regulation of antibody isotype secretion by subsets of antigen-specific helper T cells. Nature, 334, 255-258.
30. Moghaddam, A., Olszewska, W., Wang, B., et al. (2006): A potential molecular mechanism for hypersensitivity caused by formalin-inactivated vaccines. Nat. Med., 12, 905-907.
31. Spruth, M., Kistner, O., Savidis-Dacho, H., et al. (2006): A double-inactivated whole virus candidate SARS coronavirus vaccine stimulates neutralising and protective antibody responses. Vaccine, 24, 652-661.
32. Zakhartchouk, A.N., Lin, Q., Petric, M. et al. (2005): Augmentation of immune responses to SARS coronavirus by a combination of DNA and whole killed virus vaccines. Vaccine, 23, 4385-4391.
33. Hovden, A.O., Cox, R.J. and Haaheim, L.R. (2005): Whole influenza virus vaccine is more immunogenic than split influenza virus vaccine and induces primarily an IgG2a response in BALB/c mice. Scand. J. Immunol., 62, 36-44.